The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000835347p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
17/04/2026
Date registered
Help: Date registered
10/07/2026
Date last updated
Help: Date last updated
10/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Tooth-coloured alternatives (sliver nanoparticles) to silver fluoride for cavities in children
Scientific title
Aesthetic Alternatives (sliver nanoparticles Ag1 or AgL1) to Silver Fluoride for Managing Early Childhood Caries
Additional trial identifiers [1] 317041 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Dental Caries 341542 0
Early childhood caries 341543 0
Condition category
Condition code
Oral and Gastrointestinal 337613 337613 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention will involve a split-mouth design, where matched eligible teeth within the same participant will be randomly allocated to receive either conventional silver fluoride treatment using Riva Star Aqua™ (SDI Ltd, Bayswater, VIC, Australia) or one of the novel silver nanoparticle formulations. Participants will be randomised to one of two experimental formulation groups: Ag1 or AgL1. Within each participant, matched teeth will then be randomly allocated to receive either the control treatment or the allocated experimental formulation. Randomisation will be undertaken using a computer-generated randomisation sequence, and allocation will be documented in the participant’s study record.
All treatments will be administered during a single dental appointment by a registered dentist trained in the study protocol.

Riva Star Aqua™ is an ammonia-free, two-step silver fluoride system consisting of 38% silver fluoride followed by potassium iodide. Approximately 1 drop, approximately 10 µL per lesion site, will be dispensed into a disposable dappen dish and applied topically using a micro-applicator after isolation and gentle cleaning of the lesion. The silver fluoride solution will be applied for approximately 60 seconds, followed by potassium iodide application until the creamy white precipitate clears. The procedure for each lesion is expected to take approximately 5 minutes, with the total treatment appointment expected to last approximately 20–30 minutes depending on the number of lesions treated. Adherence to the intervention protocol will be monitored using standardised clinical record forms and documented in the participant’s dental records, including lesion isolation, application time, material used, and treated tooth surfaces.
The novel silver nanoparticle formulations, Ag1 and AgL1, are experimental formulations containing silver nanoparticles prepared using different formulation approaches. Ag1 contains uncapped silver nanoparticles, while AgL1 contains citrate-capped silver nanoparticles.

For all novel formulations, approximately 1–2 µL per lesion site will be applied topically using a sterile micro-applicator following standardised clinical protocols. Teeth will first be isolated and gently cleaned prior to application. The formulation will then be applied directly to the lesion surface and allowed to remain undisturbed for approximately 60 seconds. All applications will be performed by a registered dentist trained in the study protocol. The application procedure for each lesion is expected to take approximately 5 minutes, with the overall clinical appointment expected to last approximately 20–30 minutes depending on the number of lesions treated. Adherence to the intervention protocol will be monitored using standardised treatment documentation forms and participant dental records, including details of the formulation used, application duration, treated surfaces, and any adverse events or observations recorded at the time of treatment.

Both the intervention and control treatments will be administered during the same dental appointment as part of the split-mouth study design. This approach will allow each participant to receive both the control treatment and one experimental formulation within the same appointment.

The study will also investigate treatment acceptability and aesthetic perceptions of participants and/or parents through completion of a short questionnaire regarding treatment appearance, acceptability, comfort, and satisfaction following application of the materials. Participation in the questionnaire component will be voluntary and offered to all participants. The questionnaire will be completed immediately following treatment within the same appointment as the primary clinical intervention.

Intervention code [1] 333797 0
Prevention
Intervention code [2] 334067 0
Treatment: Other
Description of the comparator or control
In this study, the comparator will be conventional silver fluoride treatment (AgF/KI), which is currently used in clinical practice for caries management.
Control group
Active

Outcomes
Primary outcome [1] 345114 0
Change in caries lesion status following application of the intervention.
Timepoint [1] 345114 0
Baseline, 3 months, 6 months, and 12 months post-treatment.
Primary outcome [2] 345414 0
Tooth colour change (aesthetic outcome)
Timepoint [2] 345414 0
2 weeks, 3 months, 6 months, and 12 months post-treatment.
Primary outcome [3] 345415 0
Antimicrobial effectiveness (bacterial load): Antibacterial effect via reduction or inhibition of cariogenic bacterial activity within the carious lesion following application of the intervention.
Timepoint [3] 345415 0
Baseline, 3 months, 6 months, and 12 months post-treatment.
Secondary outcome [1] 460518 0
Need for retreatment
Timepoint [1] 460518 0
2 weeks, 3 months, 6 months, and 12 months post-treatment.
Secondary outcome [2] 460519 0
Participant/caregiver acceptability
Timepoint [2] 460519 0
2 weeks post-treatment,
Secondary outcome [3] 463555 0
Need for further intervention
Timepoint [3] 463555 0
2 weeks, 3 months, 6 months, and 12 months post-treatment.
Secondary outcome [4] 463556 0
Cost effectiveness
Timepoint [4] 463556 0
12 months post-treatment.
Secondary outcome [5] 464769 0
Pulpal Infection
Timepoint [5] 464769 0
2 weeks, 3 months, 6 months, and 12 months post-treatment.

Eligibility
Key inclusion criteria
Children aged approximately 2–10 years who present with early childhood caries and have at least one pair of comparable carious lesions (cavitated or non-cavitated) on contralateral teeth within the same arch will be invited to participate. Selected teeth must be asymptomatic or exhibit mild, reversible pulpal symptoms (e.g., non-lingering sensitivity to stimuli) with no clinical or radiographic signs of pulpal or periapical pathology. Participants must be able to attend follow-up appointments, and informed consent must be provided by a parent or guardian.
Minimum age
2 Years
Maximum age
10 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they have known allergies or sensitivities to silver, fluoride, potassium, iodine, or related compounds. Additional exclusion criteria include teeth with signs of irreversible pulpitis, abscess, sinus tract, or periapical pathology; participants who have received antibiotics recently; those with medical or behavioural conditions that would preclude safe participation or cooperation; and those who are unable to comply with study procedures or follow-up visits.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
To minimise bias, blinding will be implemented by dispensing all study agents in identical opaque (black) plastic bottles. These will be labelled by administrative staff who are not involved in the clinical procedures. As a result, both the operator and the participant will remain unaware of whether the intervention is the control (AgF) or one of the test formulations (Ag1 or AGL1).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation will be performed using a computer-generated random number generator to allocate matched teeth within each participant (split-mouth design) to either conventional silver fluoride (Riva Star Aqua™, SDI Ltd, Bayswater, VIC, Australia) or the novel silver nanoparticle formulation (Ag1 or AgL1).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
All collected data will be converted into quantitative form for analysis. Statistical analysis will be performed using GraphPad Prism (version 10) and SPSS software (Version 29, IBM Corporation, 2020). Paired statistical tests appropriate for split-mouth designs (e.g., paired t-tests, Wilcoxon signed-rank tests, and mixed-effects models) will be used to compare outcomes between intervention sites. Bivariate and multivariate analyses will be conducted where appropriate. A p-value of <0.05 will be considered statistically significant.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 321017 0
University
Name [1] 321017 0
The University of Queensland
Country [1] 321017 0
Australia
Primary sponsor type
University
Name
The University of Queensland
Address
Country
Australia
Secondary sponsor category [1] 323721 0
Commercial sector/Industry
Name [1] 323721 0
SDI Limited
Address [1] 323721 0
Country [1] 323721 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 319551 0
The University of Queensland Human Research Ethics Committee A
Ethics committee address [1] 319551 0
Ethics committee country [1] 319551 0
Australia
Date submitted for ethics approval [1] 319551 0
12/04/2026
Approval date [1] 319551 0
Ethics approval number [1] 319551 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147686 0
A/Prof Sobia Zafar
Address 147686 0
Clinical Associate Professor Sobia Zafar, Paediatric Dentistry School of Dentistry, The University of Queensland Room 7116, Level 7, 288 Herston Road, Herston QLD 4006
Country 147686 0
Australia
Phone 147686 0
+61 7 33658048
Fax 147686 0
Email 147686 0
Contact person for public queries
Name 147687 0
Sobia Zafar
Address 147687 0
Discipline Lead for Paediatric Dentistry School of Dentistry, The University of Queensland Room 7116, Level 7, 288 Herston Road, Herston QLD 4006
Country 147687 0
Australia
Phone 147687 0
+61 7 33658048
Fax 147687 0
Email 147687 0
Contact person for scientific queries
Name 147688 0
Sobia Zafar
Address 147688 0
Discipline Lead for Paediatric Dentistry School of Dentistry, The University of Queensland Room 7116, Level 7, 288 Herston Road, Herston QLD 4006
Country 147688 0
Australia
Phone 147688 0
+61 7 33658048
Fax 147688 0
Email 147688 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.